Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
Shun Lu, Terufumi Kato, Xiaorong Dong, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 7, pp. 585-597
Closed Access | Times Cited: 88

Showing 1-25 of 88 citing articles:

Non-small-cell lung cancer
Lizza Hendriks, Jordi Remón, C. Faivre‐Finn, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 43
Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
Pankaj Garg, Sulabh Singhal, Prakash Kulkarni, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 14, pp. 4189-4189
Open Access | Times Cited: 10
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
Fei Zhou, Haoyue Guo, Yang Xia, et al.
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 10
Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development
Carla Corvaja, Antonio Passaro, Ilaria Attili, et al.
Cancer Treatment Reviews (2024) Vol. 130, pp. 102824-102824
Closed Access | Times Cited: 9
Long-term outcomes of neoadjuvant gefitinib in resectable stage II-IIIA non-small cell lung cancer: A phase II, prospective cohort study
Zhanming Ma, Fangqiu Fu, Yang Zhang, et al.
Lung Cancer (2025) Vol. 201, pp. 108457-108457
Closed Access | Times Cited: 1
Oncology: What You May Have Missed in 2024
Zainab Al Maqrashi, Sze Wah Samuel Chan, Zeba Siddiqui, et al.
Annals of Internal Medicine (2025)
Closed Access | Times Cited: 1
Lung Cancer Research and Treatment: Global Perspectives and Strategic Calls to Action
May-Lucie Meyer, S. Peters, Tony Mok, et al.
Annals of Oncology (2024)
Closed Access | Times Cited: 6
Management of Stage III Non–Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update
Megan E. Daly, Navneet Singh, Nofisat Ismaila, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 25, pp. 3058-3060
Closed Access | Times Cited: 5
Early-Stage Non-Small Cell Lung Cancer: New Challenges with Immune Checkpoint Blockers and Targeted Therapies
Pernelle Lavaud, Martina Bortolot, Lodovica Zullo, et al.
Cancers (2024) Vol. 16, Iss. 16, pp. 2779-2779
Open Access | Times Cited: 5
Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial
J.H. Heinzerling, Kathryn F. Mileham, Myra Robinson, et al.
The Lancet Oncology (2024)
Closed Access | Times Cited: 5
Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study
Shun Lü, M-J Ahn, Thanyanan Reungwetwattana, et al.
Annals of Oncology (2024) Vol. 35, Iss. 12, pp. 1116-1125
Open Access | Times Cited: 4
Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancer
Stephanie P.L. Saw, Wen‐Zhao Zhong, Rui Fu, et al.
Lung Cancer (2025) Vol. 200, pp. 108076-108076
Open Access
Actualités dans le cancer broncho-pulmonaire : traitements médicaux
Gérard Zalcman
Bulletin de l Académie Nationale de Médecine (2025)
Closed Access
Full-dose SBRT for the primary tumour in stage III NSCLC: a promising and safe way to selective dose escalation?
C. Le Péchoux, Angela Botticella, Antonin Lévy
The Lancet Oncology (2025) Vol. 26, Iss. 1, pp. 3-5
Closed Access
Consolidation ALK Tyrosine Kinase Inhibitor in Definitively Treated Unresectable Stage III ALK+ NSCLC: Can Real-World Data Inform Clinical Decision in the Absence of a LAURA-Type Designed Trial?
Zhaohui Arter, Sai‐Hong Ignatius Ou, Misako Nagasaka
Journal of Thoracic Oncology (2025) Vol. 20, Iss. 1, pp. 12-16
Closed Access
Response to Letter to the Editor From Drs. Xiaowei Huang, Xian Gu, and Zhenye Xu
Amin H. Nassar, So Yeon Kim, Elio Adib, et al.
Journal of Thoracic Oncology (2025) Vol. 20, Iss. 1, pp. e2-e3
Closed Access
Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting
Pedram Yadollahi, Kelli A. McCord, Yong Li, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Efficacy and Safety of Four Weeks of Moderately Hypofractionated Chemoradiation for Unresectable, Stage 3 Non–Small Cell Lung Cancer: A Systematic Review
Joanna Ludbrook, Mahesh Kumar, Yu Yang Soon, et al.
Asia-Pacific Journal of Clinical Oncology (2025)
Closed Access
Cell-Free Circulating Tumor DNA for Non-Invasive Molecular Profiling Among Patients Undergoing Definitive Chemoradiation for Locally Advanced Lung Cancer
Emily S. Lebow, Jordan Eichholz, Lillian Boe, et al.
Advances in Radiation Oncology (2025) Vol. 10, Iss. 4, pp. 101727-101727
Open Access
Five-year outcomes with gefitinib induction and chemoradiotherapy in EGFR-mutant stage III non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study
Katsuyuki Hotta, Sho Saeki, Shinya Sakata, et al.
International Journal of Clinical Oncology (2025)
Open Access
Possibilities of Overcoming Resistance to Osimertinib in NSCLC Patients with Mutations in the EGFR Gene
Marcin Nicoś, Anna Sroka‐Bartnicka, Ewa Kalinka‐Warzocha, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 563-563
Open Access
Antibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart delivery of chemotherapy to the target
Giannis Mountzios, Stephanie P.L. Saw, Lizza Hendriks, et al.
Cancer Treatment Reviews (2025) Vol. 134, pp. 102902-102902
Closed Access
Osimertinib in the Treatment of Epidermal Growth Factor Receptor-Mutant Early and Locally Advanced Stages of Non-Small-Cell Lung Cancer: Current Evidence and Future Perspectives
Antonello Veccia, Mariachiara Dipasquale, M. Lorenzi, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 668-668
Open Access
A single-cell map of patients with non-small cell lung cancer harboring rare-driver mutations after anti-PD-1 treatment
Rui Fu, Chao Zhang, Mengmeng Song, et al.
Cancer Letters (2025) Vol. 616, pp. 217595-217595
Closed Access
InDuRanS beim lokal fortgeschrittenen NSCLC
Cas Stefaan Dejonckheere, Eleni Gkika
Forum (2025)
Closed Access
Page 1 - Next Page

Scroll to top